Amicus Therapeutics Inc. (NASDAQ:FOLD) shares saw strong trading volume on Thursday . 2,301,262 shares traded hands during mid-day trading, a decline of 1% from the previous session’s volume of 2,333,937 shares.The stock last traded at $5.94 and had previously closed at $5.68.

A number of equities research analysts have commented on FOLD shares. Leerink Swann reiterated an “outperform” rating and issued a $17.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, June 1st. Bank of America Corp. started coverage on Amicus Therapeutics in a research report on Wednesday, May 18th. They issued a “buy” rating and a $10.00 price target on the stock. Robert W. Baird started coverage on Amicus Therapeutics in a research report on Wednesday, April 13th. They issued a “neutral” rating and a $9.00 price target on the stock. Goldman Sachs Group Inc. started coverage on Amicus Therapeutics in a research report on Wednesday, March 30th. They issued a “neutral” rating and a $10.00 price target on the stock. Finally, Chardan Capital upped their price target on Amicus Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, April 12th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $12.88.

The company’s 50 day moving average is $6.29 and its 200 day moving average is $7.12. The firm’s market cap is $762.29 million.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. Equities research analysts forecast that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current year.

In other news, General Counsel Ellen Rosenberg purchased 15,000 shares of the company’s stock in a transaction on Thursday, June 2nd. The stock was purchased at an average price of $7.67 per share, with a total value of $115,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A number of large investors have recently modified their holdings of the company. Nationwide Fund Advisors raised its stake in shares of Amicus Therapeutics by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 105,597 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,754 shares during the period. ProShare Advisors LLC raised its stake in shares of Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock valued at $1,138,000 after buying an additional 15,789 shares during the period. Swiss National Bank raised its stake in shares of Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock valued at $1,360,000 after buying an additional 5,100 shares during the period. TD Asset Management Inc. raised its stake in shares of Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock valued at $1,733,000 after buying an additional 2,600 shares during the period. Finally, Columbus Circle Investors raised its stake in shares of Amicus Therapeutics by 122.7% in the fourth quarter. Columbus Circle Investors now owns 227,889 shares of the biopharmaceutical company’s stock valued at $2,211,000 after buying an additional 125,574 shares during the period.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.